share_log

卫信康:子公司撤回复方氨基酸(16)双肽(1)注射液注册申请

Wei Xinkang: Subsidiary withdraws registration application for formic amino acid (16) dipeptide (1) injection

Breakings ·  Nov 14, 2024 16:43

Weixinkang announced that Baiyi Pharmaceutical, a wholly-owned subsidiary, received the “Notice of Termination of Drug Registration Application” issued by the State Drug Administration and agreed to withdraw the registration application for the amino acid (16) dipeptide (1) injection. After the registration application is withdrawn, the company will refine and improve the research data in accordance with changes in policy and technical requirements and then submit it again. As of October 31, 2024, the company has invested about 6.7775 million yuan in R&D of this drug. This withdrawal will not have a significant impact on the company's current operations.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment